Sanofi Reports Lower Q2 Earnings, But Lifts 2023 Outlook On New Drug Launches

Sanofi SA SNY reported a 1% decline in Q2 business operating income of €2.73 billion. Business EPS of €1.74, up 0.6% on a reported basis and 8.1% at CER.

Revenues increased €9.96 billion, down 1.5% and up 3.3% at constant currency.

Specialty Care grew 11.8% to €4.4 billion, driven by Dupixent (€2.56 billion, +34.2%) and Nexviazyme (€103 million, +146.5%), more than offsetting the anticipated impact of Aubagio generic competition in the U.S.

Vaccines sales were up 9.1% Y/Y to €1.22 billion, mainly driven by Polio/Pertussis/Hib (PPH).

General Medicines sales decreased 12.8% Y/Y €3.11 billion (down 7.3% on constant currency). Core assets were down 2.9% to €1.56 billion (up 2.4% on constant currency). 

Non-core assets were lower mainly due to Lantus (€353 million, -41.2%).

Consumer healthcare sales growth continued (+0.7% on constant currency) despite unfavorable effect from inventory build in the prior quarter.

Outlook: Sanofi increased its FY23 Business EPS guidance to grow mid-single-digit at CER, citing strong sales from new drug launches, excluding the effect of currency swings. The negative currency impact on 2023 earnings is expected to be 6.5%-7.5%.

It had previously expected 2023 adjusted EPS to grow by a "low single-digit" percentage, with an additional negative currency impact of 5.5%-6.5%.

The improved outlook also includes about €400 million of expected one-off COVID-19 vaccine revenues in the second half of the year, with no further sales expected after that.

Price Action: SNY shares are down 2.13% at $52.40 during the premarket session on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!